Recent news on Refacto

No go for Novo's potential stroke therapy  -  Feb 28, 2007
DrugResearcher.com,Marketed drugs that seek to enhance coagulation are Wyeth's ReFacto and BeneFix for the treatment of haemophilia A and haemophilia B respectively.

Wyeth pens three deals in a day  -  Feb 6, 2007
In-PharmaTechnologist.com,Wyeth already has two haemophilia treatments, one for each type of the disease: ReFacto for haemophilia A and BeneFix to treat haemophilia B, currently the

Wyeth steps up research on blood  -  Feb 6, 2007
NorthJersey.com,Wyeth makes synthetic proteins to replace those missing in patients with hemophilia. The company sells Refacto for hemophilia A, the most-common form,

Wyeth enters partnerships for hemophilia treatments  -  Feb 5, 2007
Asbury Park Press,The company sells Refacto for hemophilia A, the most-common form, and Benefix for hemophilia B. Shares of Wyeth fell 11 cents, to $50.35, at 12:59 pm in New

Wyeth boosts pipeline with three deals  -  Feb 8, 2007
In-PharmaTechnologist.com,Wyeth already develops two treatments, one for each type of haemophilia: ReFacto for haemophilia A and BeneFix to treat haemophilia B.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional